Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

It is evident that obesity places huge pressures on our already heavily burdened NHS service.However, what is causing me the most annoyance is why diabetes medication is being offered to patients for ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

With an increasing need for dementia care, a new medical practice in Vienna seeks to prevent or manage dementia in its patients.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

"Our study results forecast a dramatic rise in the burden from dementia in the United States over the coming decades, with ...

Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive ...